Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Gilead spends $1.28bn on PepStar’s potential Icotyde rival | PharmaVoice

Pharma Tech

Gilead spends $1.28bn on PepStar’s potential Icotyde rival

Oct 23, 2026, 11:07 AM

Read Full Article → Gilead spends $1.28bn on PepStar’s potential Icotyde rival

Gilead spends $1.28bn on PepStar’s potential Icotyde rival

Translate article text

Choose a language and wait for the translated text.

Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast.